Azimuth Capital Trims Stake in Eli Lilly

Investment firm reduces position in pharmaceutical giant by 8.2%

Mar. 15, 2026 at 8:35am

Got story updates? Submit your updates here. ›

Azimuth Capital Investment Management LLC, an institutional investor, reduced its stake in Eli Lilly and Company (NYSE: LLY) by 8.2% during the third quarter, according to a filing with the Securities and Exchange Commission. The firm now holds 65,013 shares of the pharmaceutical company's stock, valued at $49.61 million.

Why it matters

Eli Lilly is one of the world's largest pharmaceutical companies, known for developing innovative medicines across a range of therapeutic areas. Institutional investors closely monitor their holdings in Lilly and other major drug makers, as changes in ownership can signal broader market trends or shifts in investor sentiment.

The details

According to the SEC filing, Azimuth Capital Investment Management sold 5,794 shares of Eli Lilly during the third quarter, reducing its total position to 65,013 shares. The firm's holdings in Lilly now account for approximately 1.8% of its overall investment portfolio, making it the 6th largest position.

  • Azimuth Capital reduced its Eli Lilly stake during the third quarter of 2026.

The players

Azimuth Capital Investment Management LLC

An institutional investment firm that manages assets on behalf of clients.

Eli Lilly and Company

A global pharmaceutical company that researches, develops, manufactures and commercializes a broad range of medicines and therapies.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Azimuth Capital's Eli Lilly position, while relatively small, could signal a broader shift in investor sentiment around the pharmaceutical sector as a whole. Institutional ownership changes are closely watched by analysts and investors for clues about the market's outlook on major companies.